Literature DB >> 33609480

Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Peter Hermann1, Brian Appleby2, Jean-Philippe Brandel3, Byron Caughey4, Steven Collins5, Michael D Geschwind6, Alison Green7, Stephane Haïk3, Gabor G Kovacs8, Anna Ladogana9, Franc Llorens10, Simon Mead11, Noriyuki Nishida12, Suvankar Pal7, Piero Parchi13, Maurizio Pocchiari9, Katsuya Satoh14, Gianluigi Zanusso15, Inga Zerr16.   

Abstract

Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused by misfolded prion proteins (PrPSc). Effective therapeutics are currently not available and accurate diagnosis can be challenging. Clinical diagnostic criteria use a combination of characteristic neuropsychiatric symptoms, CSF proteins 14-3-3, MRI, and EEG. Supportive biomarkers, such as high CSF total tau, could aid the diagnostic process. However, discordant studies have led to controversies about the clinical value of some established surrogate biomarkers. Development and clinical application of disease-specific protein aggregation and amplification assays, such as real-time quaking induced conversion (RT-QuIC), have constituted major breakthroughs for the confident pre-mortem diagnosis of sporadic Creutzfeldt-Jakob disease. Updated criteria for the diagnosis of sporadic Creutzfeldt-Jakob disease, including application of RT-QuIC, should improve early clinical confirmation, surveillance, assessment of PrPSc seeding activity in different tissues, and trial monitoring. Moreover, emerging blood-based, prognostic, and potentially pre-symptomatic biomarker candidates are under investigation.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33609480      PMCID: PMC8285036          DOI: 10.1016/S1474-4422(20)30477-4

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  108 in total

1.  Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Authors:  Eric Vallabh Minikel; Eric Kuhn; Alexandra R Cocco; Sonia M Vallabh; Christina R Hartigan; Andrew G Reidenbach; Jiri G Safar; Gregory J Raymond; Michael D McCarthy; Rhonda O'Keefe; Franc Llorens; Inga Zerr; Sabina Capellari; Piero Parchi; Stuart L Schreiber; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2019-09-26       Impact factor: 5.911

2.  The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases.

Authors:  Matthias Schmitz; Maria Cramm; Franc Llorens; Dominik Müller-Cramm; Steven Collins; Ryuichiro Atarashi; Katsuya Satoh; Christina D Orrù; Bradley R Groveman; Saima Zafar; Walter J Schulz-Schaeffer; Byron Caughey; Inga Zerr
Journal:  Nat Protoc       Date:  2016-10-13       Impact factor: 13.491

3.  Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.

Authors:  André Karch; Franc Llorens; Matthias Schmitz; Amandeep Singh Arora; Saima Zafar; Peter Lange; Christian Schmidt; Inga Zerr
Journal:  J Alzheimers Dis       Date:  2016-10-18       Impact factor: 4.472

Review 4.  Towards a treatment for genetic prion disease: trials and biomarkers.

Authors:  Sonia M Vallabh; Eric Vallabh Minikel; Stuart L Schreiber; Eric S Lander
Journal:  Lancet Neurol       Date:  2020-03-18       Impact factor: 44.182

5.  Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease.

Authors:  André Karch; Peter Hermann; Claudia Ponto; Matthias Schmitz; Amandeep Arora; Saima Zafar; Franc Llorens; Annika Müller-Heine; Inga Zerr
Journal:  Neurobiol Aging       Date:  2015-02-07       Impact factor: 4.673

6.  Diagnosis of Prion Diseases by RT-QuIC Results in Improved Surveillance.

Authors:  Daniel D Rhoads; Aleksandra Wrona; Aaron Foutz; Janis Blevins; Kathleen Glisic; Marissa Person; Ryan A Maddox; Ermias D Belay; Lawrence B Schonberger; Curtis Tatsuoka; Mark L Cohen; Brian S Appleby
Journal:  Neurology       Date:  2020-06-22       Impact factor: 9.910

7.  Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays.

Authors:  Jason M Wilham; Christina D Orrú; Richard A Bessen; Ryuichiro Atarashi; Kazunori Sano; Brent Race; Kimberly D Meade-White; Lara M Taubner; Andrew Timmes; Byron Caughey
Journal:  PLoS Pathog       Date:  2010-12-02       Impact factor: 6.823

8.  Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study.

Authors:  Michael B Coulthart; Gerard H Jansen; Elina Olsen; Deborah L Godal; Tim Connolly; Bernard C K Choi; Zheng Wang; Neil R Cashman
Journal:  BMC Neurol       Date:  2011-10-27       Impact factor: 2.474

9.  Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease.

Authors:  Maria Cramm; Matthias Schmitz; André Karch; Eva Mitrova; Franziska Kuhn; Bjoern Schroeder; Alex Raeber; Daniela Varges; Yong-Sun Kim; Katsuya Satoh; Steven Collins; Inga Zerr
Journal:  Mol Neurobiol       Date:  2015-04-01       Impact factor: 5.590

10.  Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.

Authors:  Samir Abu Rumeileh; Francesca Lattanzio; Michelangelo Stanzani Maserati; Romana Rizzi; Sabina Capellari; Piero Parchi
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

View more
  44 in total

Review 1.  RT-QuIC as ultrasensitive method for prion detection.

Authors:  Ryuichiro Atarashi
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

Review 2.  Gene expression and epigenetic markers of prion diseases.

Authors:  Emmanuelle A Viré; Simon Mead
Journal:  Cell Tissue Res       Date:  2022-03-21       Impact factor: 5.249

Review 3.  The risk of Creutzfeldt-Jakob disease infection in cadaveric surgical training.

Authors:  Keiko Ogami-Takamura; Kazunobu Saiki; Daisuke Endo; Kiyohito Murai; Toshiyuki Tsurumoto
Journal:  Anat Sci Int       Date:  2022-03-21       Impact factor: 1.741

4.  Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis.

Authors:  Bryce K Chang; Gregory S Day; Jonathan Graff-Radford; Andrew McKeon; Eoin P Flanagan; Alicia Algeciras-Schimnich; Michelle M Mielke; Aivi Nguyen; David T Jones; Michel Toledano; Walter K Kremers; David S Knopman; Ronald C Petersen; Wentao Li
Journal:  Eur J Neurol       Date:  2022-07-05       Impact factor: 6.288

5.  Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.

Authors:  Matthias Schmitz; Sezgi Canaslan; Juan Carlos Espinosa; Natalia Fernández-Borges; Anna Villar-Piqué; Franc Llorens; Daniela Varges; Fabian Maass; Juan Maria Torres; Peter Hermann; Inga Zerr
Journal:  Mol Neurobiol       Date:  2022-06-18       Impact factor: 5.682

Review 6.  Rapidly Progressive Dementia.

Authors:  Gregory S Day
Journal:  Continuum (Minneap Minn)       Date:  2022-06-01

Review 7.  Clinical Use of Improved Diagnostic Testing for Detection of Prion Disease.

Authors:  Mark P Figgie; Brian S Appleby
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 8.  Protein Aggregation Landscape in Neurodegenerative Diseases: Clinical Relevance and Future Applications.

Authors:  Niccolò Candelise; Silvia Scaricamazza; Illari Salvatori; Alberto Ferri; Cristiana Valle; Valeria Manganelli; Tina Garofalo; Maurizio Sorice; Roberta Misasi
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

9.  Detection of Prions in Brain Homogenates and CSF Samples Using a Second-Generation RT-QuIC Assay: A Useful Tool for Retrospective Analysis of Archived Samples.

Authors:  Tibor Moško; Soňa Galušková; Radoslav Matěj; Magdalena Brůžová; Karel Holada
Journal:  Pathogens       Date:  2021-06-13

10.  Diagnostic and prognostic performance of CSF α-synuclein in prion disease in the context of rapidly progressive dementia.

Authors:  Andrea Mastrangelo; Simone Baiardi; Corrado Zenesini; Anna Poleggi; Angela Mammana; Barbara Polischi; Anna Ladogana; Sabina Capellari; Piero Parchi
Journal:  Alzheimers Dement (Amst)       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.